作者：于一江
單位：淮安市中醫院內分泌科
來源：醫學界內分泌頻道
01
02
03
04
05
06
參考文獻：
[1]何秉賢.二甲雙胍在高血壓防治中應用的現代觀點[J].中華高血壓雜志,2018,26(06):508-509.
[2]Racine Jenna L,Adams Jacquelyn H,Antony Kathleen M,el.Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.[J].American journal of perinatology,2021,38(11).
[3]Ouyang Hong,AlMureish Abdulrahman,Wu Na.Research progress of metformin in gestational diabetes mellitus:a narrative review.[J].Annals of palliative medicine,2021,10(3).
[4]楊周生,陳曉宇.二甲雙胍多效能藥理作用的研究進展[J].中國臨床新醫學,2021,14(04):422-426.
[5]許桂炎,應曉蕾,曹海輝.二甲雙胍治療高血壓并發代謝綜合征的臨床效果[J].全科醫學臨床與教育,2017,15(01):89-91.
[6]蘇馨,胡蓉.高血壓合并糖尿病血壓控制的探討[J].重慶醫學,2018,47(16):2219-2222.
[7]劉思緒,于勝欽,張曙影.阿卡波糖心血管獲益機制及安全性的研究進展[J].實用心腦肺血管病雜志,2019,27(11):102-106.
[8]周鶴銘,周雁蘋.吡格列酮輔助治療老年2型糖尿病并高血壓的可行性[J].慢性病學雜志,2019,20(09):1384-1385+1388.
[9]臧永軍,龍朦朦,劉東,等.吡格列酮治療2型糖尿病的研究進展[J].中國醫藥指南,2017,15(36):4-5.
[10]張秀龍,占長河.吡格列酮聯合阿卡波糖治療老年2型糖尿病并高血壓的臨床療效[J].臨床合理用藥雜志,2019,12(09):11-12+14.
[11]Kvandova M,Barancik M,Balis P,Puzserova A,Majzunova M,Dovinova I.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability,renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.[J].Journal of physiology and pharmacology:an official journal of the Polish Physiological Society,2018,69(2).
[12]郭彩紅,高秀瑩.達格列凈對2型糖尿病伴代謝綜合征患者代謝指標影響[J].臨床軍醫雜志,2018,46(05):585-587.
[13]郝雁紅,吳清,李云,等.達格列凈在2型糖尿病合并高血壓患者中的臨床應用[J].中國當代醫藥,2021,28(18):12-16.
[14]王菲,盧新政.卡格列凈對2型糖尿病患者心血管保護作用的研究進展[J].心血管病學進展,2020,41(03):231-234.
[15]陳添玉,陳琪瑩,張月珍.卡格列凈對2型糖尿病患者心血管因素影響的Meta分析[J].藥物流行病學雜志,2021,30(04):239-244+288.
[16]Kario Kazuomi,Okada Kenta,Kato Mitsutoshi,Nishizawa Masafumi,Yoshida Tetsuro,Asano Tsuguyoshi,Uchiyama Kazuaki,Niijima Yawara,Katsuya Tomohiro,Urata Hidenori,Osuga Jun-Ichi,Fujiwara Takeshi,Yamazaki Shoji,Tomitani Naoko,Kanegae Hiroshi.24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension:Results from the Randomized,Placebo-Controlled SACRA Study.[J].Circulation,2018,139(18).
[17]周佩,唐湘宇,鄧云霞,等.SGLT-2抑制劑——恩格列凈的心血管保護作用及機制研究進展[J].中國醫藥導刊,2021,23(11):823-827.
[18]孫永,田琳,吳讓兵,等.2型糖尿病治療新藥恩格列凈的研究現狀[J].中國糖尿病雜志,2018,26(06):523-528.
[19]Dilip Sharma,Suril Verma,Shivani Vaidya,el.Recent updates on GLP-1 agonists:Current advancements&challenges[J].Biomedicine&Pharmacotherapy,2018,108.
[20]趙延珍,杜婧.GLP-1受體激動劑治療2型糖尿病的研究進展[J].老年醫學研究,2021,2(03):55-60.
[21]陳涯,王艷萍,張亮,等.利拉魯肽對2型糖尿病合并動脈粥樣硬化患者血糖、血脂、血壓和頸動脈斑塊的影響[J].海南醫學院學報,2019,25(10):730-734.
[22]徐慶海,馬穎,吳艷春,等.利拉魯肽對2型糖尿病合并高血壓患者血糖、血壓及血脂的影響[J].山東醫藥,2017,57(21):77-79.
[23]Younes Subhi Talal,Maeda Kenji J,Sasser Jennifer,el.The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.[J].American journal of physiology.Heart and circulatory physiology,2020,318(1).
[24]張學輝,李娟.利拉魯肽降壓效應機制的研究進展[J].臨床醫學研究與實踐,2021,6(08):196-198.
[25]Zhang Jianqiang,Chen Qiuyue,Zhong Jixin,Liu Chaohong,Zheng Bing,Gong Quan.DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy:Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.[J].Frontiers in immunology,2019,10.
[26]杜鎣漩,王慧.西格列汀對糖尿病合并高血壓患者血壓、動脈僵硬度和內皮功能的影響[J].廣西醫學,2020,42(10):1193-1197.
[27]陳昇.西格列汀輔助治療糖尿病并高血壓對患者糖脂代謝、血管內皮功能的影響[J].糖尿病新世界,2020,23(24):91-93+102.
